Randomised study assessing efficacy and safety of telaprevir evey 8 or 12 hours with peginterferon alfa 2b and ribavirin in HCV patients

Trial Profile

Randomised study assessing efficacy and safety of telaprevir evey 8 or 12 hours with peginterferon alfa 2b and ribavirin in HCV patients

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2013

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Nov 2013 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 22 May 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 25 Feb 2013 Planned number of patients changed from 80 to 50 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top